| |
Wednesday, April 9, 2025 | 10am ET / 7am PT Learn the key steps for successfully entering Japan’s pharmaceutical market. This webinar covers regulatory requirements, compliance strategies, supply chain best practices, and common challenges. Gain expert insights to navigate this high-potential market with confidence. Don’t miss out—register now to secure your spot! 
|
|
Today’s Big NewsApr 3, 2025 |
|
Wednesday, April 9, 2025 | 11am ET / 8am PT Health systems around the globe face a difficult paradox: delivering more care with fewer resources. In this exclusive webinar, our expert panel will explore how AI-based solutions are addressing these challenges with real-world examples, experience, and published outcomes in ASCO and Nature. Register now. 
|
|
| By Fraiser Kansteiner On Wednesday, President Donald Trump unveiled another wave of tariffs but did not mention pharmaceutical-specific tariffs. Plus, pharmaceuticals are included in a list of products exempt from the new round of reciprocal duties. |
|
|
|
By James Waldron BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT antibody. |
By Conor Hale The German conglomerate said the deal would not only add to its work in artificial intelligence and digital twins but would also help it provide customers with a more seamless connection between research and manufacturing. |
By Kevin Dunleavy In response to a request from the European Medicines Agency following the death of a 16-year-old patient in the U.S., Sarepta and Roche have temporarily halted three clinical trials in Europe of their Duchenne muscular dystrophy gene therapy Elevidys. |
|
Thursday, April 10, 2025 | 11am ET / 8am PT Cell and gene therapies offer hope for previously untreatable diseases, with viral vectors currently favored as the primary gene delivery method. However, the complexities pose key challenges. In this webinar, learn how to choose the right production platform for achieving commercial timelines and managing manufacturing costs. Register now. 
|
|
By Zoey Becker Camilla Sylvest is stepping down from her role as executive vice president, commercial strategy and corporate affairs after nearly three decades of service to the Danish drugmaker. |
By Gabrielle Masson The California biotech will use the cash infusion to support its pipeline of allogeneic cell therapy candidates for chronic neurological disorders, including its lead candidate that takes aim at a common form of epilepsy. |
By Fraiser Kansteiner Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 shot. The missed deadline comes shortly after the departure of the FDA's chief vaccine official Peter Marks, M.D., Ph.D., and as wider concerns mount about an anti-vaccine agenda under HHS secretary Robert F. Kennedy Jr. |
By Nick Paul Taylor Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. An early look at the phase 1b/2a data showed amyloid levels fell below a disease threshold in 81% of patients after 28 weeks. |
By Andrea Park As Nxera Pharma proceeds into the “next era” implied by its name—following a rebrand from Sosei Group last year—the Japanese drugmaker is adding a new executive to help guide its growth plans. |
By Darren Incorvaia Struggling Cyclacel Pharmaceuticals is dropping one of its two clinical-stage assets in an effort to save cash, the company’s new owners announced on Apr. 2. |
By Nick Paul Taylor Agencies made moves on both sides of the Atlantic Wednesday, with Havas Health signing up leaders in the U.S. and Real Chemistry unveiling appointments to boost its presence in Europe. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we hear from Nada Hanafi, co-founder of MedTech Color, about the importance of diversity in healthcare settings. |
|
|---|
|
|
|
Antibody-drug conjugates (ADCs) and radioisotope therapies (RITs) offer targeted therapies that effectively attack tumor cells while minimizing harm to surrounding healthy tissue. However, the right design of ADC and RIT trials is critical. Access this report to learn about the pivotal role of advanced medical imaging. Download here. 
|
|
Research We interviewed 15 biopharma leaders on the critical success factors for building a Best Practice customer-facing organization. This report shares what we learned. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Read about four trends that will shape the innovations, therapies, & market landscape in oncology during 2025 & beyond. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to revolutionize your vaccine trials with Avacare's latest white paper. Gain exclusive access to innovative, data-driven recruitment strategies that ensure diverse, efficient, and high-quality vaccine trials. Sponsored by: Avacare Clinical Research Network |
Whitepaper Develop your CAR molecule faster Sponsored by: Cell Signaling Technology |
| Accepting Nominations Now |
|
| Accepting Nominations Now |
|
|
| |
|
